论文部分内容阅读
目的:应用免疫组化法,检测COX-2、TRX-1在乳腺癌组织中表达,探讨COX-2、TRX-1表达与乳腺癌临床病理特征及预后因素的关系。方法:122例乳腺癌组织石蜡标本制作成乳腺癌组织芯片。免疫组化SP法检测COX-2、TRX-1表达。所有患者均接受规范性手术、术后辅助化疗及放疗,激素受体阳性病人接受5年的内分泌治疗。从手术日期到复发转移或随访截止日期(2008年7月)确定为患者无病生存期。共有45例复发转移病例。结果:122例乳腺癌组织中COX-2、TRX-1均呈高表达,分别为58.2%、54.1%,且二者表达呈正相关(r=0.286,P=0.001);COX-2表达与临床分期(r=0.193,P=0.033)、肿块大小(r=0.192,P=0.034)及淋巴结转移(r=0.186,P=0.040)呈正相关,TRX-1表达与临床分期(r=0.206,P=0.023)、肿块大小(r=0.236,P=0.009)呈正相关,与淋巴结转移(r=0.175,P=0.054)不相关。COX-2或TRX-1表达与无病生存期呈负相关(P=0.027,P=0.046);COX-2和TRX-1共表达与无病生存期呈负相关(P=0.017)。结论:乳腺癌组织中COX-2、TRX-1均呈高表达,两者与乳腺癌患者预后密切相关;COX-2、TRX-1表达呈正相关,推测乳腺癌组织中TRX-1可能参与COX-2调节。
OBJECTIVE: To detect the expression of COX-2 and TRX-1 in breast cancer by immunohistochemistry and to explore the relationship between the expression of COX-2 and TRX-1 and the clinicopathological features and prognosis of breast cancer. Methods: 122 cases of breast cancer tissue paraffin specimens made into breast cancer tissue chip. Immunohistochemical SP method was used to detect the expression of COX-2 and TRX-1. All patients received normative surgery, postoperative adjuvant chemotherapy and radiotherapy, hormone receptor-positive patients received 5 years of endocrine therapy. The patient’s disease-free survival was determined from the date of surgery to the time of recurrence or follow-up (July 2008). A total of 45 cases of recurrence and metastasis. Results: The expressions of COX-2 and TRX-1 were all significantly higher in 122 cases of breast cancer (58.2% and 54.1%, respectively), and the expressions of COX-2 and TRX- The expression of TRX-1 was positively correlated with clinical stage (r = 0.206, P = 0.033), tumor size (r = 0.192, P = 0.034) and lymph node metastasis = 0.023), tumor size (r = 0.236, P = 0.009), but not lymph node metastasis (r = 0.175, P = 0.054) The expression of COX-2 or TRX-1 was negatively correlated with disease-free survival (P = 0.027, P = 0.046). Co-expression of COX-2 and TRX-1 was negatively correlated with disease-free survival (P = 0.017). CONCLUSIONS: The expression of COX-2 and TRX-1 in breast cancer tissues is highly correlated with the prognosis of breast cancer patients. The expressions of COX-2 and TRX-1 are positively correlated, suggesting that TRX-1 may be involved in the expression of COX -2 adjustment.